A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Conditions: Malignant Pleural Mesothelioma Interventions: Drug: Lenvatinib; Drug: Pemetrexed; Drug: Cisplatin/Carboplatin; Drug: Pembrolizumab Sponsors: Hyogo Medical University; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials
Exercise to Boost Immunity in Advanced Cancer
Conditions: Mesothelioma; Lung; Pancreatic Cancer Interventions: Other: Exercise Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield; Sheffield Hallam University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Conditions: Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma; Endometrial Cancer; Adenocarcinoma of Lung; Triple Negative Breast Cancer; Liposarcoma; Leiomyosarcoma; Mesothelioma, Malignant; Adenocarcinoma - Gastroesophageal Junction (GEJ); Adenocarcinoma of the Stomach; Melanoma, Malignant; Renal Cell Carcinoma Interventions: Biological: NM32-2668 Sponsors: Numab Therapeutics AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
Conditions: Mesothelioma, Malignant; Carcinoma, Non-Small-Cell Lung; Carcinoma Breast Stage IV; Ovarian Cancer; Esophageal Cancer; Gastric Cancer Interventions: Drug: Cisplatine Teva ® Sponsors: Dr Jean Yannis PERENTES Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Conditions: Malignant Mesothelioma; Colorectal Cancer; Bile Duct Cancer; Rectal Cancer; Ovary Cancer; Pancreatic Cancer; Breast Cancer Female Interventions: Biological: UCMYM802 Injection Sponsors: UTC Therapeutics Inc.; Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
SW-682 in Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Mesothelioma, Malignant Interventions: Drug: SW-682; Drug: Combination Therapy Sponsors: SpringWorks Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
GPC3/Mesothelin-CAR- γδT Cells Against Cancers
Conditions: Pancreas Cancer; Lung Cancer; Liver Cancer; Mesothelioma; CAR-T Cell Therapy; Solid Tumor, Adult Interventions: Biological: Cell therapy for solid tumors Sponsors: Second Affiliated Hospital of Guangzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
Conditions: Pleural Mesothelioma Interventions: Drug: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab Sponsors: Istituto Oncologico Veneto IRCCS; MSD Italia S.r.l. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Conditions: Unresectable Pleural Mesothelioma Interventions: Drug: Volrustomig; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Nivolumab; Drug: Ipilimumab Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Conditions: Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer Interventions: Drug: Milademetan; Drug: Atezolizumab Sponsors: Rain Oncology Inc Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Conditions: Malignant Peritoneal Mesothelioma; Peritoneal Mesothelioma; Mesothelioma; Mesothelioma, Malignant; Malignant Mesothelioma Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin Sponsor: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Conditions: Malignant Peritoneal Mesothelioma; Peritoneal Mesothelioma; Mesothelioma; Mesothelioma, Malignant; Malignant Mesothelioma Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Conditions: Solid Tumor, Adult; Colorectal Cancer; NSCLC; Non Small Cell Lung Cancer; NSCLC, Recurrent; Non-Small Cell Squamous Lung Cancer; Pancreas Cancer; Pancreatic Neoplasm; Colorectal Adenocarcinoma; CRC; Colon Cancer; Rectal Cancer; Cancer; Ovar ian Cancer; Ovarian Neoplasms; Mesothelioma; Mesothelioma, Malignant; Ovary Cancer; Lung Cancer; MESOM Interventions: Biological: A2B694; Diagnostic Test: xT CDx with HLA-LOH Assay Sponsors: A2 Biotherapeutics Inc.; Tempus Labs Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
